A Comparison of Short- and Long-Term Therapeutic Outcomes of Infliximab- versus Tacrolimus-Based Strategies for Steroid-Refractory Ulcerative Colitis

<div>Colectomy-free rate at 2 months. Colectomy-free rate at 2 months was 91.7% in the infliximab group and 85.1% in the tacrolimus group, without a significant difference between the two groups.</div>

Gastroenterology Research and Practice

fig2

Figure 2

Figure 2: A Comparison of Short- and Long-Term Therapeutic Outcomes of Infliximab- versus Tacrolimus-Based Strategies for Steroid-Refractory Ulcerative Colitis 

Figure 2 | A Comparison of Short- and Long-Term Therapeutic Outcomes of Infliximab- versus Tacrolimus-Based Strategies for Steroid-Refractory Ulcerative Colitis 